financetom
Business
financetom
/
Business
/
Infosys CEO says attrition going down every quarter, expects deal wins to continue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Infosys CEO says attrition going down every quarter, expects deal wins to continue
Jan 12, 2023 10:52 AM

Global tech behemoth Infosys had a strong quarter with large deal wins, according to CEO Salil Parekh. The company does not provide quarterly guidances. However, he said the EBIT margin for the full year will be at the lower end of the guided range of 21-22 percent YoY.

Speaking to CNBC-TV18, Parekh said, “We had a very good operating margin in Q3 at 21.5 percent. We have kept the guidance (for the year), which was narrow, to 21-22 percent. We have also made the statement in the comments earlier — it will be at the lower end of the guidance.”

He added, “We have had a very strong large deals win for this for Q3, and we have had very strong growth in the quarter of 13.7 percent.”

Read Here | Infosys Q3 Results | Full year revenue guidance raised, deal wins strongest in eight quarters

The company has two engines of growth: Digital and cloud, and automation and cost efficiency. Parekh expects the deal wins to continue in the coming quarters, but did not provide a time frame for when sectors such as BFSI, hi tech, and telecom will turn around.

Lower attrition

Infosys has also seen a reduction in attrition, with Parekh noting that the company has made several changes and implemented policies that have helped with a sharp reduction in attrition.

He said, “Attrition is going down every quarter for us. There were several policies that we put in place, several changes, much more aligned with the employee expectations, career development, training, and many of those things, (that) I believe are helping us with very sharp six-point reduction attrition this quarter, but also in the previous quarters.”

Also Read | Infosys hiring hits a 9-quarter low but attrition rate eases to 24.3% in Q3

The stock closed at Rs 1,482.95, up 0.8 percent, on Thursday.

(Edited by : Shoma Bhattacharjee)

First Published:Jan 12, 2023 7:52 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Model N to Be Acquired by Vista Equity Partners for $1.25 Billion in Cash
Model N to Be Acquired by Vista Equity Partners for $1.25 Billion in Cash
Apr 8, 2024
08:22 AM EDT, 04/08/2024 (MT Newswires) -- Vista Equity Partners has entered into a definitive merger agreement to acquire Model N ( MODN ) , for $1.25 billion in an all-cash transaction, Model N ( MODN ) said Monday. Price: 29.49, Change: +2.4, Percent Change: +8.86 ...
Boeing Says Departing Chief Executive Received $32.8 Million Pay Package in 2023
Boeing Says Departing Chief Executive Received $32.8 Million Pay Package in 2023
Apr 8, 2024
08:21 AM EDT, 04/08/2024 (MT Newswires) -- Boeing's ( BA ) departing Chief Executive David Calhoun received a total compensation of about $32.8 million in 2023, up from his $22.6 million pay package in 2022, according to a regulatory filing Friday. Calhoun, who announced his resignation from the company in March amid concerns about Boeing ( BA ) planes' quality,...
Blackstone to take Apartment Income REIT private for $10 bln, WSJ reports
Blackstone to take Apartment Income REIT private for $10 bln, WSJ reports
Apr 8, 2024
April 8 (Reuters) - Asset manager Blackstone is taking private rental housing firm Apartment Income REIT ( AIRC ) , known as AIR Communities, for $10 billion in cash, the Wall Street Journal reported on Monday, citing people familiar with the matter. (Reporting by Ananta Agarwal in Bengaluru; Editing by Arun Koyyur) ...
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
Apr 8, 2024
08:22 AM EDT, 04/08/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) and Legend Biotech ( LEGN ) said the US Food and Drug Administration has approved Carvykti to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. In 2017, Legend entered into a worldwide license and collaboration agreement with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved